免疫代谢对瘤微环境的不适应
Emma S Hathaway1, Erin Q Jennings2, Jeffrey C Rathmell3,4
1Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.
Cold Spring Harbor perspectives in medicine
|March 4, 2024
概括
瘤微环境 (TME) 的代谢适应会损害免疫细胞功能,阻碍抗瘤免疫力. 解决这些代谢挑战对于改善癌症免疫疗法和T细胞疗法至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 代谢过程中的代谢.
背景情况:
- 瘤包括癌细胞和各种免疫透物.
- 在瘤微环境 (TME) 内的免疫细胞代谢尚不清楚.
- 在TME中的代谢适应阻碍了T细胞和巨细胞的功能.
研究的目的:
- 审查免疫细胞在固体瘤中的代谢适应.
- 探索代谢性免疫抑制的驱动因素.
- 为了突出癌症免疫治疗的含义.
主要方法:
- 在TME中对T细胞和巨细胞代谢的文献综述.
- 分析代谢适应及其对免疫效应器功能的影响.
- 综合与代谢性免疫抑制相关的发现.
主要成果:
- 对TME的代谢适应,包括营养物质的枯竭和废物积累,抑制免疫细胞.
- 特定的免疫细胞子集表现出独特的代谢要求和不适应性反应.
- 通过后翻译性修改进行代谢信号传递,有助于免疫抑制.
结论:
- 了解TME中的免疫细胞代谢对于克服治疗阻力至关重要.
- 准代谢途径可以增强抗瘤免疫力.
- 解决代谢性免疫抑制是促进癌症免疫疗法和CAR T细胞疗法的关键.
相关概念视频
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Cell-mediated Immune Responses
68.3K
Overview
68.3K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


